PharmaTher Holdings Ltd. PHRRF Open PharmaTher Holdings Ltd. in new tab

Company Profile

PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company's product pipeline includes KETARX, a ketamine hydrochloride injection for the treatment of Parkinson's disease, Amyotrophic Lateral Sclerosis, complex regional pain, and anesthesia, procedural sedation as well as depression, surgical and pain management. It develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX wearable pump for the maintenance of general anesthesia for diagnostic, surgical procedures and pain indications. In addition, the company offers PHARMAPATCH, a microneedle patch technology solution, which includes hydrogel-forming and gelatin methacryloyl delivery system for the treatment of psychedelics and infectious diseases. Further, it has license agreement with BioRAE, Inc. for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle; and the University of Kansas to develop and commercialize the intellectual property of ketamine to treat ALS; with the University of Arizona for the development and commercialization of ketamine in the treatment of Parkinson's disease; as well as holds a patent and know-how license agreement with The Queen's University of Belfast to develop and commercialize hydrogel-forming microneedle patch delivery technology. The company was incorporated in 2019 and is headquartered in Toronto, Canada.